Cancer Treatment Reviews 39 (2013) 622–631 Contents lists available at SciVerse ScienceDirect Cancer Treatment Reviews journal homepage: www.elsevierhealth.com/journals/ctrv Anti-Tumour Treatment HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials Susan Dent a,1, Basak Oyan b,2, Arnd Honig c,3, Max Mano d,4, Sacha Howell e,⇑ a The Ottawa Hospital Cancer Centre, Division of Medical Oncology, Department of Medicine, The University of Ottawa, 501 Smyth Road, Box 912, Ottawa, Ontario, Canada Medical Oncology Section, Yeditepe University Hospital, Devletyolu, Ankara Cad 102-104, Istanbul, Kozyatagi 34752, Turkey c University of Wuerzburg, Josef-Schneider Str. 4, 97080 Würzburg, Germany d Instituto do Câncer do Estado de São Paulo, University of São Paulo, Av. Dr. Arnaldo, 251 Cerqueira César, São Paulo/SP, Brazil e The University of Manchester, Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, United Kingdom b a r t i c l e i n f o Article history: Received 23 July 2012 Received in revised form 7 January 2013 Accepted 10 January 2013 Keywords: Neoadjuvant breast cancer Pathological complete response Trastuzumab Lapatinib Pertuzumab Novel agents HER2 a b s t r a c t Targeting human epidermal growth factor receptor 2 (HER2) during or in sequence with chemotherapy improves overall survival in metastatic and early HER2-overexpressing breast cancer. In this paper we systematically review neoadjuvant clinical trial data in HER2-positive breast cancer and discuss key unanswered clinical questions. All trials of HER2-targeted neoadjuvant therapy were identiﬁed through non-date-limited searches of PubMEDÒ and BiosisÒ and congress abstract book searches from 2000–2011. Eligible trials were prospective, had at least 10 patients and a clear deﬁnition of pathological complete response (pCR) rate. A total of 50 trials fulﬁlled the eligibility criteria; 41 single-arm phase II studies were identiﬁed, 37 with trastuzumab and 4 with lapatinib, with signiﬁcant variability in baseline tumour characteristics and pCR rates (range 12–66.7%). Of 9 randomised phase II/III trials, 4 assessed the addition of trastuzumab to chemotherapy and a further 5 randomised trials assessed different HER2-targeting approaches. Four of these studies assessed dual HER2-targeting approaches, which universally increased pCR at the expense of increased non-cardiac toxicity when lapatinib, but not pertuzumab, was added to trastuzumab. Signiﬁcant advances have been made in HER2 targeting, resulting in a marked increase in the number of breast cancer patients experiencing tumour pCR. Mature data from randomised neoadjuvant and adjuvant studies are awaited for survival outcomes with combination targeted approaches. Unanswered questions centre on the individualisation of therapy and include; which, if any, chemotherapy backbone should be used, and which patients need dual HER2 blockade? Ó 2013 Elsevier Ltd. All rights reserved. Introduction Neoadjuvant therapy in women with early breast cancer improves rates of operability in locally advanced disease and breast conservation in women who would otherwise require a mastectomy.1,2 However, meta-analyses of neoadjuvant trials have not shown an improvement in disease-free (DFS) or overall survival ⇑ Corresponding author. Address: The University of Manchester, Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, United Kingdom. Tel.: +44 161 4463721; fax: +44 161 4468564. E-mail addresses: [email protected] (S. Dent), [email protected] (B. Oyan), [email protected] (A. Honig), [email protected] (M. Mano), [email protected] (S. Howell). 1 Tel.: +1 613 737 7700; fax: +1 613 247 3511. 2 Tel.: +90 216 578 4085; fax: +90 216 578 4969. 3 Tel.: +49 179 944 3540; fax: +49 931 201 25406. 4 Tel.: +55(11)38932619; fax: +55(11)38933504. 0305-7372/$ - see front matter Ó 2013 Elsevier Ltd. All rights reserved. http://dx.doi.org/10.1016/j.ctrv.2013.01.002 (OS) compared to similar treatment delivered after breast surgery.1,2 Nevertheless, the neoadjuvant approach offers additional advantages in the assessment of response to both standard therapies and novel agents requiring in vivo validation. Several classiﬁcation systems deﬁning the histopathological effects of chemotherapy on breast cancer have been published.3–7 In clinical trials, pathological complete response (pCR) has been used as a surrogate marker for clinical outcome (including OS) for patients receiving neoadjuvant treatment. Inconsistencies in the deﬁnition of pCR have resulted in signiﬁcant variations reported in the literature.8,9 The most widely accepted deﬁnition of pCR is no residual invasive carcinoma in the breast and axillary lymph nodes. Differences in the deﬁnition of pCR hinge on the requirement for clearance of ductal carcinoma in situ in addition to invasive cancer only from the breast, and invasive disease from axillary lymph nodes. Ideally, to aid in the critical evaluation of results, a standardised deﬁnition of pCR should be utilised for all clinical trials. S. Dent et al. / Cancer Treatment Reviews 39 (2013) 622–631 Human epidermal growth factor receptor 2 (HER2) ampliﬁcation is seen in approximately 20% of breast cancers and is associated with more aggressive disease and worse prognosis.10 Trastuzumab, a monoclonal antibody against the extracellular component of the HER2 protein, results in improved DFS and OS in patients with HER2-overexpressing tumours in both the adjuvant and metastatic settings.11–13 In the neoadjuvant setting, the achievement of pCR with chemotherapy plus trastuzumab has been shown to correlate well with improved survival outcomes.14 More recently, additional HER2-targeted therapies including lapatinib (a tyrosine kinase inhibitor) and pertuzumab (a humanised anti-HER2 monoclonal antibody) have shown promising results in metastatic breast cancer leading to the exploration of dual blockade with a combination of targeted therapies in the neoadjuvant setting. In this article, we systematically review the literature detailing HER2-targeted approaches in neoadjuvant clinical trials. Pathological complete response rates achieved with a wide range of regimens in phase II and III studies are tabulated and toxicity proﬁles, particularly in phase III studies, are discussed. Consideration is given to key questions that remain unanswered such as the optimal management of women with residual cancer post-neoadjuvant therapy and strategies to tailor therapy and increase pCR rates. Methods Eligible trials were identiﬁed through searches of PubMEDÒ, BiosisÒ and manual searches of congress abstract books from the American Society of Clinical Oncology (ASCO), San Antonio Breast Cancer Symposium (SABCS), European Cancer Organisation (ECCO), European Society for Medical Oncology (ESMO), European Breast Cancer Conference (EBCC) and St. Gallen International Breast Cancer Conference (St. Gallen). No time limit was stipulated for the PubMED searches. Conference proceedings from 2005 to 2011 were searched initially and the search expanded to 2000 to 2005 post hoc. The PubMED search terms were: [HER2+, or HER-2+, or HER-2+, or HER2-positive, or HER2 positive, or HER-2 positive, or ErbB-2 positive, or ERbB2 positive] AND [trastuzumab, or pertuzumab, or T-DM1, or lapatinib, or neratinib, or HER2-targeted treatment, or anti-HER-2 treatment, or anti-HER2 treatment, or any of the previous terms with ‘therapy’ substituted for ‘treatment’] AND [breast cancer, or breast neoplasm] AND [neoadjuvant, or preoperative, or pre-operative, or primary systemic]. Search limits were set to: clinical trials, randomised trials, meta-analyses, phase II, or phase III. PubMED was searched for evidence of subsequent publication of conference abstracts using the senior author as the search term. Abstracts without evidence of prospective enrolment of at least 10 patients into a phase II or III trial were excluded, as were studies with no clear deﬁnition of pCR unless clariﬁcation could be obtained from the conference poster or presentation. If multiple reports on the same dataset were found, only the most recent update was included. Two authors (Sacha Howell and Basak Oyan) reviewed the resulting lists of studies to be included, and consensus was obtained from all authors for disagreements. Pathological complete response rates were transcribed as presented if adequate account was made of all recruited patients in the text of the abstract/publication. Where there was discrepancy, the number recruited was used as the denominator to provide intent-to-treat analysis. In addition to pCR rates, data were collected on tumour size, stage, endocrine receptor status, presence of inﬂammatory breast cancer, chemotherapy/targeted agent regimen, as well as treatment schedule and duration. ClinicalTrials.gov was also searched for ongoing trials for discussion. 623 Results Summary of neoadjuvant trastuzumab studies The search criteria identiﬁed 358 studies although 308 did not meet the eligibility criteria (Fig. 1). Fifty articles met the eligibility criteria and were included in the review. The majority (37 articles) reported on single-arm phase II studies15–51 of different chemotherapy backbones with trastuzumab (Supplementary Table 1). A further four single-arm phase II trials examining the role of single HER2 blockade with lapatinib are summarised in Table 1.52–55 Four randomised trials evaluated the role of single-agent trastuzumab added to a chemotherapy backbone versus the same chemotherapy alone (Table 2).56–59 A further ﬁve randomised trials evaluated the beneﬁt of other HER2 blockade approaches, including four studies on dual-HER2 blockade (Table 3).60–64 Single-arm phase II trastuzumab trials In the single-arm phase II studies (Supplementary Table 1), which evaluated chemotherapy backbones on a background of single-agent trastuzumab, pCR rates varied widely (range 12–76%).15– 51 Cross-trial comparison of the relative activity of these regimens has many pitfalls given the variability in disease stage, oestrogen receptor (ER) status, deﬁnitions of pCR, as well as the many potential biases inherent to non-randomised studies. Despite these caveats, these trials demonstrated that trastuzumab is active when given in combination with a wide range of different chemotherapy regimens. In addition, they raised important questions for testing in randomised clinical trials, including the role of anthracyclines in sequence or combination with trastuzumab, the optimal taxane partner for trastuzumab, the role of other non-taxane, non-anthracycline agents and novel targeted therapies. Single-arm lapatinib trials Two single-arm studies have explored the combination of lapatinib and trastuzumab (Table 1).52,53 Chang et al. treated women with relatively large tumours (median tumour size 6 cm) with 12 weeks of lapatinib and trastuzumab without the addition of chemotherapy.52 Women with ER-positive cancers also received letrozole with or without goserelin in order to block ER/HER crosstalk. The overall rate of pCR in the breast was 28%. Despite treatment with endocrine therapy, patients with ER-positive tumours achieved a lower pCR rate (21%) compared to those with ER-negative expression (42%). The omission of chemotherapy was associated with a good toxicity proﬁle. Callahan et al. presented preliminary safety and efﬁcacy data on the combination of trastuzumab and lapatinib with docetaxel and carboplatin for six q3-weekly cycles.53 In the ﬁrst 21 patients (including six in a dose escalation phase), the pCR rate of 43% was achieved with ‘manageable’ toxicity. In two small trials (involving 30 and 32 patients, respectively), lapatinib was added to a taxane (nab-paclitaxel or paclitaxel) chemotherapy backbone with pCR rates of 17.9% and 9.4%, respectively.54,55 Randomised trials of chemotherapy ± trastuzumab A total of four randomised (phase II and III) clinical trials have investigated the addition of trastuzumab to neoadjuvant chemotherapy (Table 2).56–59 Overall, these trials reported an increase in pCR rates with the addition of trastuzumab to chemotherapy (pCR 26–65%), compared to chemotherapy alone (pCR 19–27%). This appears to be relatively independent of the type of chemotherapy employed. In the ﬁrst of these studies (MDACC), women 624 S. Dent et al. / Cancer Treatment Reviews 39 (2013) 622–631 Fig. 1. HER2 = human epidermal growth factor receptor 2, pCR = complete pathological response (deﬁned as no invasive tumour in breast and axilla, if not otherwise speciﬁed), EBC = early breast cancer, DCIS = ductal carcinoma in situ, ST1 = supplementary table 1, T1 = table 1, T3 = table 3. Table 1 Single-arm lapatinib trials. Ref. # Study name, phase N Regimen Neo tx duration, weeks Stage HR negative,% pCR,% 52 TBCRC 006 RP2 Chang, et al. J Clin Oncol 2011 66 12 >3 cm or >2 cm and cN+ 38 28 (61 cm residual invasive tumour in breast) ER+: 21 ER-: 42 53 RP2 Callahan, et al. Cancer Res 2010 20 21 IIA 40% IIB 35% IIIA 10% IIIB 15% 40 43 54 Kaklamani, et al. Breast Cancer Res Treat 2012 30 12 17.9 P2 Boussen, et al. J Clin Oncol 2010 32 I 13.3% II 63.3 III 23.4% IIIB 44% IIIC 34% IVa 22% IBC = 100% 60 55 T + L ± gosrelin 12 (Tqwk) + L 1000 mg for 12 weeks If ER+, postmenopausal: letrozole If ER+, premenopausal: letrozole + gosrelin T + L DCar + T + L 1 (Tq3wk + L 1000 mg, 3 wks) ? 6 (Tq3wk) + 6 (L 1000 mg/d, q3wk) + 6 (D 75 mg/m2 Car AUC: 5–6, q3wk) Nab-P + L 4 (Nab-P 260 mg/m2, q3wk) + (L 1000 mg/d 12 weeks) L?L+P L 1500 mg for 2 weeks ? L 1500 mg + 12 (P 80 mg/m2, qwk) Not given 9.4% 14 Ref. # = reference number, Neo tx = neoadjuvant treatment, HR = hormone receptor, pCR = pathological complete response (deﬁned as no invasive tumour in breast and axilla, if not otherwise speciﬁed), RP2 = randomised phase II study, T = trastuzumab, L = lapatinib, Tqwk = 4 mg/kg loading then 2 mg/kg every week, wks = weeks, ER = oestrogen receptor, D = docetaxel, Car = carboplatin, Tq3wk = 8 mg/kg loading then 6 mg/kg every 3 weeks, q3wk = every 3 weeks, AUC = area under the concentration–time curve, Nab-P = nanoparticle albumin-bound paclitaxel, P2 = phase II study, P = paclitaxel, qwk = every week. a All patients planned for surgery before starting therapy. were randomised to block sequential taxanes and anthracycline chemotherapy with or without trastuzumab throughout treatment.56 This approach re-explored the concept of concurrent administration of anthracycline and trastuzumab, which had largely been abandoned after high rates of cardiac failure were seen in the metastatic setting.11,56 The pCR rate in the combination arm was 65% compared to only 26% in those receiving chemother- apy alone, resulting in early closure of the study (n = 42). Safety data were relatively reassuring. The high pCR rates were shown to be reproducible in a small expansion phase of the trial and the regimen was shown to be feasible outside of a clinical trial setting.56,65,66 In the larger NOAH study (randomised phase III), 235 patients with HER2-positive, locally advanced breast cancer (including 625 S. Dent et al. / Cancer Treatment Reviews 39 (2013) 622–631 Table 2 Randomised trials of chemotherapy ± trastuzumab. Ref. # Study name, phase, citation 56 MDACC RP3 Buzdar, et al. J Clin Oncol 2005 57 NOAH RP3 Gianni, et al. Lancet 2010 58 RP2 Pierga, et al. Breast Cancer Res Treat 2010 59 ABCSG-24 RP3 Steger, et al. Cancer Res 2009 N 42 235 120 90 Regimen Neo tx duration, weeks Stage HR negative,% pCR,% Arm A: P ? FEC Arm B: P + T ? FEC + T 4 (P 225 mg/m2 over 24 h, q3wk) ± 12 (Tqwk) ? 4 (FEC 500[d1,4]/75/500 mg/m2, q3wk) ± 12 (Tqwk) Arm A: AP ? P ? CMF Arm B: AP + T ? P + T ? CMF + T 3 (AP 60/150 mg/m2, q3wk) ? 3 (P 175 mg/m2, q3wk) ? 3 (CMF 600/40/600 mg/m2 d1,8, q4wk) ± Tq3wk with AP and P, q4wk with CMF 24 T1 10% T2 67% T3 21% T4 2% 43 Arm A: 26 Arm B: 65.2 P = 0.016 40 T3N1 or T4 or any T N2,3 T4a-c 42.5% IBC = 26.5% 64 Total pCR Arm A: 19% Arm B: 38% Arm A: EC ? D Arm B: EC ? D + T 4 (EC 75/750 mg/m2, q3wk) ? 4 (D 100 mg/m2, q3wk) + 12 (Tqwk) Arm A: ED ± Cap Arm B: ED ± Cap + T 6 (ED 75/75 mg/m2 q3wk) ± 6 (Cap 1000 mg/m2 bid, d1–14, q3wk) ± 6 (Tq3wk) 24 T2 > 4 cm N0T2 49% T3 36 T4 15% T1 19% T2 52% T3 25% T4 4% 41 18 40 P = 0.001 Breast pCR Arm A: 22% Arm B: 43% P = 0.0007 Arm A: 19 Arm B: 26 P = not given Arm A: 26. Arm B: 40 P = 0.369 pCR deﬁnition not provided. Ref. # = reference number, Neo tx = neoadjuvant treatment, HR = hormone receptor, pCR = pathological complete response (deﬁned as no invasive tumour in breast and axilla, if not otherwise speciﬁed), RP3 = randomised phase III study, P = paclitaxel, FEC = 5-ﬂuorouracil, epirubicin, and cyclophosphamide, T = trastuzumab, q3wk = every 3 weeks, Tqwk = 4 mg/kg loading then 2 mg/kg every week, d = day, A = doxorubicin, CMF = cyclophosphamide, methotrexate, and 5-ﬂuorouracil, q4wk = every 4 weeks, Tq3wk = 8 mg/kg loading then 6 mg/kg every 3 weeks, IBC = inﬂammatory breast cancer, RP2 = randomised phase II study, E = epirubicin, C = cyclophosphamide, D = docetaxel, Cap = capecitabine, bid = twice daily. inﬂammatory breast cancer) were randomised to receive epirubicin/taxane/CMF-based chemotherapy with or without trastuzumab, concurrent with all chemotherapy.57 The primary endpoint was event-free survival (EFS), which was improved with the addition of trastuzumab (3-year EFS 71% vs. 56%, hazard ratio 0.59 [95% CI, 0.38 to 0.90]; P = 0.013), as was the secondary endpoint of pCR rate (total pCR: 38% vs. 19%, P = 0.001; breast pCR: 43% vs. 22%, P = 0.0007). The investigational arm appeared to be safe, with no major short term cardiac issues reported. The patients in the NOAH trial had more advanced disease than those in the MDACC trial (69%57 had T4 and/or inﬂammatory breast cancer compared with 67%56 with T2 disease in the MDACC trial), which may explain the lower pCR rates observed. In a French randomised phase II trial, 120 patients with stage II and III HER2-positive breast cancer were randomised to receive epirubicin/cyclophosphamide followed by docetaxel with or without concurrent trastuzumab.58 In this trial, pCR rates favoured the experimental arm (26% vs. 19%), with no major safety issues reported. Similarly, in ABCSG-24, a subgroup of 90 patients with HER2-positive, locally advanced disease were randomised to receive epirubicin/docetaxel or epirubicin/docetaxel/capecitabine with or without trastuzumab, and a statistically non-signiﬁcant increase in pCR was observed with the addition of trastuzumab (40% vs. 26.7%).59 These results have led to the adoption of combination chemotherapy and trastuzumab as the standard of care in the neoadjuvant setting for women with HER2-overexpressing nonmetastatic breast cancer.67–69 Strategies to improve on trastuzumab-based therapy Despite the improved pCR rates seen with the addition of trastuzumab to chemotherapy (Table 2), the majority of patients with breast cancer do not experience a pCR and even if this is achieved a small minority still experience relapse.14 Thus in cancers where the HER2 pathway is the key driver of cell proliferation and cell survival, primary and acquired resistance to trastuzumab are key issues. Some potential mechanisms of resistance and strategies to overcome them are presented in Table 4. Dual blockade with a combination of targeted therapies has been explored as an alternative treatment strategy to overcome resistance. Although several novel agents targeting HER2 have been developed, the most mature data are available for lapatinib and pertuzumab (Table 152– 55 and Table 3.60–64) Randomised trials comparing HER2-targeting approaches Five randomised neoadjuvant trials that compared HER2-targeted agents individually or in combination were identiﬁed (Table 3).60–64 The targeted therapies in each study were combined with conventional chemotherapy backbones comprising taxanes and/or anthracyclines. In the open-label NeoALTTO trial, patients received paclitaxel with lapatinib, trastuzumab, or the combination.60 The pCR rate in the breast and axilla with the combination of lapatinib and trastuzumab (46.8%) was signiﬁcantly superior to that of trastuzumab alone (27.6%; P = 0.0007). No signiﬁcant difference in pCR rates was seen between the lapatinib (20%) and trastuzumab (27.6%) arms despite one-third (33.8%) of patients treated with lapatinib not completing therapy (vs. 8% in the trastuzumabonly arm) primarily due to increased grade 3 diarrhoea (23.4% vs. 2.0%) and liver enzyme alterations (17.5% vs. 7.4%). In contrast, the GeparQuinto study examined the addition of trastuzumab or lapatinib to anthracycline-/taxane-based chemotherapy, and demonstrated a signiﬁcantly superior pCR rate in patients treated with trastuzumab (30.3% vs. 22.7%; odds ratio 0.68 [95% CI, 0.47 to 0.97]; P = 0.04).61 Dose reductions were again more common with lapatinib than trastuzumab (32% vs. 1%; P < 0.0001) and the protocol was amended to mandate a reduction in lapatinib dose from 1250 mg to 1000 mg. However, when patients without dose reductions were compared, a similar difference in the pCR rates was seen in favour of trastuzumab. A STEPP analysis performed by the investigators demonstrated no effect on pCR rates with lapatinib doses from 700 to 1250 mg. Two smaller neoadjuvant studies have compared targeted therapy with trastuzumab, lapatinib or the combination added to a chemotherapy backbone.62,63 In both of these studies, treatment 626 S. Dent et al. / Cancer Treatment Reviews 39 (2013) 622–631 Table 3 Randomised trials comparing HER2-targeting approaches. Ref. # Study name, phase, citation N Regimen Neo tx duration, weeks Stage 60 NeoALTTO RP3 Baselga, et al. Lancet 2012 455 18 >2 cm T2 58% T3/4 42% 49 Arm A: 27.6 Arm B: 20.0 Arm C: 46.8 61 GeparQuinto, GBG 44 RP3 Untch, et al. Lancet Oncol 2012 615 Arm A: T ? T + P 6 (Tqwk) ? 12 (Tqwk) + 12 (P 80 mg/m2, qwk) Arm B: L ? L + P L 1500 mg/d 6 weeks ? (L 1500 mg/d 12 weeks) + 12 (P 80 mg/m2, qwk) Arm C: T + L ? T + L + P 6 (Tqwk) + (L 1500 mg/d 6 weeks) ? 18 (Tqwk) + (L 1000 mg/ d 18 weeks) + 12 (P 80 mg/m2, qwk) Arm A: EC + T ? D + T 4 (EC 90/600 mg/m2, q3wk) + 4 (Tq3wk) ? 4 (D 100 mg/m2, q3wk) + 4 (Tq3wk) Arm B: EC + L ? D + L 4 (EC 90/600 mg/m2, q3wk) + (L 1000–1250 mg/d 12 weeks) ? 4 (D 100 mg/m2, q3wk) + (L 1000–1250 mg/d 12 weeks) 24 44 Arm A: 30.3 Arm B: 22.7 P = 0.04 62 Holmes, et al. J Clin Oncol 2011 100 T3/4a-d or HR-, T2 N+and HR+, T1 pNSLN+ HR+, cT4 – 18% IBC = 2.5% II-III 63 CHER-LOB RP2 Guarneri, et al. J Clin Oncol 2012 80 64 NeoSphere RP2 Gianni, et al. Lancet Oncol 2012 417 Arm A: T ? FEC + T ? P + T 2 (Tqwk) ? 4 (FEC 500/75/500 mg/m2, q3wk) + 12 (Tqwk) ? 12 (P 80 mg/m2, qwk) + 12 Tqwk) Arm B: L ? FEC + L ? P + L (L 1250 mg/d 2 weeks) ? 4 (FEC 500/75/500 mg/m2, q3wk) + (L 1250 mg/d 12 weeks) ? 12 (P 80 mg/m2, qwk) + (L 1250 mg/ d 12 weeks) Arm C: T + L ? FEC + T + L ? P + T + L 2 (Tqwk) + (L 750 mg/d 2 wk) ? 4 (FEC 500/75/500 mg/m2, q3wk) + 12 (Tqwk) + (L 750 mg/d 12 weeks ? 12 (P 80 mg/m2, qwk) + 12 (Tqwk) + (L 750 mg/d 12 weeks) Arm A: P + T ? FEC + T 12 (P 80 mg/m2, qwk) + 12 (Tqwk) ? 4 (FEC 500/75/500 mg/m2, q3wk) + 12 (Tqwk) Arm B: P + L ? FEC + L 12 (P 80 mg/m2, qwk) + (L 1250 mg/d 12 weeks) ? 4 (FEC 500/75/ 500 mg/m2, q3wk) + (L 1250 mg/d 12 weeks) Arm C: P + T + L ? FEC + T + L 12 (P 80 mg/m2, qwk) + 12 (Tqwk) + (L 750 mg/d 12 weeks) ? 4 (FEC 500/75/500 mg/m2, q3wk) + 12 (Tqwk) + (L 750 mg/d 12 weeks) Arm A: D + T 4 (D 75–100 mg/m2, q3wk) + 4 (Tq3wk) Arm B: D + T + Pert 4 (D 75–100 mg/m2, q3wk) + 4 (Tq3wk) + 4 (Pert 840 ? 420 mg/m2, q3wk) Arm C: T + Pert 4 (Tq3wk) + 4 (Pert 840 ? 420 mg/m2, q3wk) Arm D: D + Pert 4 (D 75–100 mg/m2, q3wk) + (Pert 840 ? 420 mg/m2, q3wk) 26 HR negative,% Not given pCR,% ⁄⁄ Arm A: 54 Arm B: 45 Arm C: 74 24 IIA 32% IIB 50% IIIA 18% 41 Arm A: 25 Arm B: 26.3 Arm C: 46.7 12 II-III LABC = 32% IBC = 7% 52 Arm 21.5 Arm 39.3 Arm 11.2 Arm 17.7 A: B: C: D: pCR deﬁnition not provided. Ref. # = reference number, Neo tx = neoadjuvant treatment, HR = hormone receptor, pCR = pathological complete response (deﬁned as no invasive tumour in breast and axilla, if not otherwise speciﬁed), RP3 = randomised phase III study, T = trastuzumab, P = paclitaxel, Tqwk = 4 mg/kg loading then 2 mg/kg every week, qwk = every week, L = lapatinib, wk = week, E = epirubicin, C = cyclophosphamide, D = docetaxel, q3wk = every 3 weeks, Tq3wk = 8 mg/kg loading then 6 mg/kg every 3 weeks, IBC = inﬂammatory breast cancer, FEC = ﬂuorouracil, epirubicin, and cyclophosphamide, RP2 = randomised phase II study, Pert = pertuzumab, LABC = locally advanced breast cancer. comprised sequential blocks of taxane then anthracycline-containing chemotherapy. The study of Holmes et al.62 reported very high pCR rates although did not deﬁne pCR (trastuzumab 54%; lapatinib 45%; trastuzumab combined with lapatinib 74%), whereas in the CHER-LOB study63 the rates of pCR (trastuzumab 25%; lapatinib 26%; trastuzumab combined with lapatinib 47%) were comparable to those in the shorter taxane-only regimen of NeoALTTO,60 highlighting the importance of adequate endpoint deﬁnition to aid comparisons between trials. The four-arm randomised phase II NeoSphere study64 (Table 3) compared the combination of pertuzumab and trastuzumab with or without docetaxel and single-agent trastuzumab or pertuzumab in combination with docetaxel. Treatment was given for a total of 12 weeks prior to surgery and all patients then received additional anthracycline-based chemotherapy postoperatively. The pertuzumab and trastuzumab combination without docetaxel induced pCR in breast and axilla in 11.2% and in breast alone in 16.8% of women. The combination of dual HER2 targeting with chemotherapy resulted in a signiﬁcantly higher pCR rate (39.3%) when compared with the same chemotherapy and single agent trastuzumab (21.5%; P = 0.014) or pertuzumab (17.7%; P = 0.003). Importantly, the addition of a second, targeted anti-HER2 agent did not increase toxicity signiﬁcantly. In the adjuvant setting, the combination of pertuzumab and trastuzumab with chemotherapy is being evaluated in the international, multicentre, randomised phase III BIG 4-11 trial (APHINITY; NCT01358877). Two further neoadjuvant studies are exploring single-agent versus combination lapatinib and trastuzumab in the neoadjuvant setting on a paclitaxel backbone, either with (NSABP-B4170) or without (CALGB 40601; NCT00770809) preoperative anthracycline prior to commencing HER2-targeted therapy. NSABP-B41 reported initial results after the searches for this article were conducted, and demonstrated high rates of breast and axillary pCR with AC-paclitaxel in combination with either trastuzumab (pCR 52.5%) or S. Dent et al. / Cancer Treatment Reviews 39 (2013) 622–631 627 Table 4 Mechanisms of resistance to trastuzumab and strategies to overcome resistance. Resistance mechanism Potential strategies to overcome resistance Obstacles for trastuzumab binding to HER2 Masking of epitope by mucin 4 and CD44-hyaluronan complex Expression of truncated HER2 protein: p95 ErbB2 Competition with circulating extracellular domain of HER2 Stabilisation and shuttling of HER2 to the cell membrane HSP activity Upregulation of HER2 downstream signalling pathways HER tyrosine kinase inhibitor (lapatinib, neratinib, afatinib) PTEN loss PI3k mutation Downregulation of p27 (Cdk inhibitor) Signalling through alternate pathways IGF-1R c-met Signalling through other members of HER family (HER2:HER3 dimerisation) Failure to trigger immune-mediated mechanisms to destroy tumour cells Low afﬁnity polymorphic forms of Fcc Epitope masking HSP inhibitors Inhibiting downstream pathways (PI3k/Akt, mTOR inhibitors), or increasing cytotoxicity of trastuzumab (T-DM1), or increasing immunity (ertumaxomab) Inhibiting activity of other receptors IGF-1R inhibitors c-met inhibitors Inhibition of dimerisation (pertuzumab) HER3 or pan-HER inhibitors (neratinib, afatinib) Increasing immunity (ertumaxomab, HER2 vaccines) HER2 = human epidermal growth factor receptor 2, HSP = heat shock protein, PTEN = phosphatase and tensin homolog, PI3k = phosphatidylinositol 3-kinase, Akt = protein kinase B, mTOR = mammalian target of rapamycin, IGF-1R = insulin-like growth factor-1 receptor. lapatinib (pCR 53.2%).70 There was no statistically signiﬁcant difference in pCR rate with chemotherapy and trastuzumab alone vs. the combination of lapatinib and trastuzumab (52.5% vs. 62% P = 0.095). Targeted agents and toxicity Cardiac toxicity Cardiac toxicity was the predominant adverse effect identiﬁed with trastuzumab in the metastatic breast cancer clinical trials (CHF 27%11,12). However, unlike the irreversible, dose-dependent apoptosis and necrosis of cardiomyocytes induced by anthracyclines,71 trastuzumab induced cardiac toxicity appears to be largely reversible. Similarly, the effects of lapatinib on the myocardium appear largely reversible, not cumulative or dose related, and ultrastructural myocardial changes are not generally seen.72 Pertuzumab has been generally well tolerated by patients enrolled in ongoing clinical trials, with a low incidence of cardiac dysfunction.73 The potential clinical beneﬁt of concurrent administration of anthracyclines and trastuzumab has been re-explored in the neoadjuvant setting in several randomised studies with no apparent detrimental impact on cardiac health. One should remain cautious however when considering adoption of this approach outside of the clinical trial setting, given the small numbers of highly selected patients enrolled in these studies and the short duration of follow-up.29,56,57,59,61–64 Cardiotoxicity in trials of dual HER2 inhibition – trastuzumab with lapatinib or pertuzumab In the NeoALLTO study (Table 3), patients received anthracycline-based chemotherapy postoperatively with concurrent administration of lapatinib, or trastuzumab, or both. No major cardiac dysfunction has been reported to date.60 Similarly in GeparQuinto, the concurrent administration of trastuzumab or lapatinib with epirubicin/cyclophosphamide-docetaxel resulted in low levels of symptomatic cardiotoxicity (1%).61 In the NeoSphere study, the addition of pertuzumab to trastuzumab resulted in only one reported case of congestive heart failure in a woman with a history of coronary stents and cardiac treatment with digitalis for an unrelated cardiac problem.64 Changes in left ventricular ejection fraction were within 15% in all of the trastuzumab, pertuzumab, and combination groups, suggesting that the addition of pertuzumab over a short course of four cycles of chemotherapy did not add signiﬁcantly to short term cardiotoxicity.64 These results are encouraging; however, we await the longer term safety data, in particular from the adjuvant portion of this trial in which anthracyclines were delivered with concurrent trastuzumab following surgery. Most recently, the TRYPHAENA study73 tested the addition of pertuzumab and trastuzumab to both anthracycline and taxane portions of neoadjuvant chemotherapy or to the taxane portion only. The primary endpoint of the study was cardiac safety. The results showed no increase in cardiotoxicity when targeted treatment was delivered with the anthracycline portion concurrently. Similarly, low levels of short-term cardiotoxicity were seen in this study with six cycles of non-anthracycline chemotherapy and trastuzumab plus pertuzumab. To date, the limited data available on dual targeted therapies does not suggest an increase in cardiac toxicity. This is reﬂected in the change in the trastuzumab label to include its use in the neoadjuvant setting in combination with chemotherapy. However, the duration of follow-up has been relatively short and as such, the widespread adoption of concurrent anthracyclines with trastuzumab in a ‘real world’ setting is premature. Bozovic-Spasojevic et al.74 undertook a combined analysis of 3 neoadjuvant trials29,56,57 in which anthracyclines were combined with trastuzumab. The concurrent use of anthracycline-based chemotherapy and trastuzumab was associated with a trend towards an increased risk of cardiac toxicity (OR 1.95, 95% CI 1.16–3.29; P = 0.36), thus highlighting the need for extra vigilance when considering the adoption of this treatment approach in the non-clinical trial setting. Non-cardiac toxicity with HER2-targeted therapies While most attention has focused on the potential cardiac toxicity of HER2-targeted therapies, several signiﬁcant non-cardiac toxicities have been observed in phase II/III clinical trials. In NeoALLTO, women randomised to the lapatinib-containing arms experienced signiﬁcant grade 3/4 diarrhoea (21% lapatinib; 23% 628 S. Dent et al. / Cancer Treatment Reviews 39 (2013) 622–631 lapatinib/trastuzumab).60 Similar rates of diarrhoea have been reported in smaller phase II neoadjuvant trials,54,63 necessitating extra vigilance in toxicity monitoring and supportive care measures. In the run-in portion of the GeparQuinto trial,61 82% of the 60 patients enrolled in the lapatinib arm experienced grade 3/4 neutropenia necessitating the mandatory administration of growth factors for patients randomised to lapatinib and docetaxel in the main study. In addition, 34.5% of patients in the run-in phase discontinued treatment early, leading to a reduction in the dose of lapatinib from 1250 mg/day to 1000 mg/day in the main study. In NeoSphere, the addition of pertuzumab to trastuzumab in combination with docetaxel did not signiﬁcantly increase toxicity.64 There were numerically more cases of grade 3/4 asthenia (2% vs. 0%) in the triple therapy arm but the incidence of grade 3/4 neutropenia was lower (45% vs. 57%). The incidence of febrile neutropenia (7% vs. 8%) as well as grade 3/4 diarrhoea (6% vs. 4%) was similar in both arms. In contrast, the addition of pertuzumab to trastuzumab and docetaxel in the metastatic setting resulted in signiﬁcantly more grade 3/4 diarrhoea (7.9% vs. 5.0%),75 possibly reﬂecting the longer duration of exposure in this trial. In NeoSphere, the combination of pertuzumab plus trastuzumab without docetaxel was very well tolerated, with only 7% of patients experiencing any grade 3/4 toxicity, conﬁrming that the majority of side effects of combination therapy are due to the cytotoxic agents.64 It is imperative that we continue to prospectively collect information on the toxicities of these targeted therapies not only in the clinical trial setting but also in clinical practise. Longer follow-up of targeted therapy trials, particularly in those patients treated with curative intent, are needed to establish the long-term safety of these agents. Novel HER2-targeted agents in ongoing neoadjuvant clinical trials Neratinib Neratinib, similar to lapatinib, is an oral, dual-activity but irreversible pan-inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinases. It targets EGFR, HER2, and HER4,76 and is an active agent in patients whose disease has progressed following trastuzumab-based therapy.77 A randomised phase II study (NSABP FB-7) of neratinib versus trastuzumab in combination with weekly paclitaxel, followed by doxorubicin and cyclophosphamide as neoadjuvant therapy is currently recruiting women with HER2-positive, locally advanced breast cancer (NCT01008150). Neratinib is also one of several investigational agents to be tested in the neoadjuvant I-SPY 2 trial on a backbone of paclitaxel followed by doxorubicin/cyclophosphamide (NCT01042379). Trastuzumab-emtansine (T-DM1) T-DM1 is a novel agent, comprised of trastuzumab, a stable linker, and emtansine, a potent microtubule inhibitor.78,79 Upon binding to HER2, T-DM1 is internalised and emtansine is released intracellularly, causing direct cytotoxicity80 thus T-DM1 requires only HER2 expression for activity not a functional HER2 signalling pathway. A phase II trial evaluating the safety and efﬁcacy of TDM1 in the neoadjuvant/adjuvant setting after the completion of anthracycline-based chemotherapy in patients with early HER2positive breast cancer has completed accrual (NCT01196052) and a neoadjuvant comparison of T-DM1 versus trastuzumab in combination with endocrine therapy is actively recruiting (NCT01745965). Afatinib (BIBW 2992) Afatinib is a potent, irreversible receptor tyrosine kinase inhibitor targeting HER1 and HER2. The drug has been tested in a small, three-arm neoadjuvant study as a single-agent compared with lapatinib or trastuzumab (each given for 6 weeks prior to deﬁnitive breast surgery) and results are pending (NCT00826267). A second single arm study, currently recruiting is assessing the efﬁcacy and safety of afatinib in combination with trastuzumab and paclitaxel prior to an anthracycline and trastuzumab combination and breast surgery (NCT01594177). Discussion The addition of HER2-targeted agents to a chemotherapy backbone in the neoadjuvant setting, has resulted in improved pCR rates (26–65%) over the same chemotherapy partner alone (19– 28%) in women with HER2-ampliﬁed breast cancers.56–59 However, a number of women treated with this approach (single HER2 blockade/chemotherapy) will not achieve a pCR and it is in this population that dual HER2 blockade may be beneﬁcial. Several trials have demonstrated the clinical beneﬁt of dual HER2 blockade in addition to a chemotherapy backbone.60,62–64 Mature data from these and ongoing adjuvant trials such as ALTTO (NCT00490139) and APHINITY (NCT01358877) are needed to establish the value of dual HER2 blockade on DFS and OS. In addition, the feasibility of dual HER2 blockade in the non-clinical trial setting is dependent on the toxicity proﬁle of these combinations as discussed previously. A number of clinical trials have tested the combination of anthracyclines given concurrently with anti-HER2 therapy, a practise largely abandoned due to high rates of cardiac toxicity observed with this approach in the metastatic setting. None of these trials have shown signiﬁcant increase in short-term cardiac toxicity57 and the trastuzumab label has recently been changed by the European Medicines Agency (EMA)80 to include treatment ‘in combination with neoadjuvant chemotherapy’, which could contain an anthracycline. However, no study has yet shown a signiﬁcant improvement in pCR rate or any survival endpoint with the addition of a HER2-targeted agent to both the anthracycline and taxane portion of a regimen versus the taxane portion alone, or indeed to taxane-based chemotherapy plus a HER2-targeted agent in the absence of an anthracycline. Indeed in TRYPHAENA73 the pCR rates and incidence of short-term cardiotoxicity were comparable in all three arms. Until the time that such outcome data, and indeed longer term cardiotoxicity data are available, regimens that employ concurrent anthracycline and HER2-targeted agents should be reserved for patients who fulﬁl the strict entry criteria and monitoring requirements of the studies in which these regimens were tested. The optimal duration of neoadjuvant therapy is not clear. Although six to eight cycles of chemotherapy prior to surgery is established practise, the impressive pCR rate with only 12 weeks of dual HER2-targeted agents plus chemotherapy in the NeoSphere64 and NeoALTTO60 studies suggest that shorter durations of highly active regimens may be feasible. As all patients had treatment postoperatively to balance out the chemotherapy regimens in these trials, future studies will be required to determine the optimal duration of neoadjuvant therapy. The optimal duration of trastuzumab therapy has not been established. Current guidelines suggest that completion of 1 year of HER2-targeted therapy is considered standard.67,68 Shorter durations may be similarly efﬁcacious81 but further trials are underway to test this hypothesis such as SOLD (NCT00593697), PERSEPHONE (NCT00712140), and PHARE (NCT00381901). Preliminary results from PHARE, designed to test 6 months vs. 12 months of adjuvant trastuzumab using a non-inferiority design, were recently presented.82 The conclusion was that 6 months of treatment could not be classed as non-inferior to 12 months statistically. Retrospective sub-group analysis suggested that the 6-month regimen may be inferior in women S. Dent et al. / Cancer Treatment Reviews 39 (2013) 622–631 with ER-negative disease who received sequential chemotherapy then trastuzumab, although this did not reach statistical signiﬁcance. Perhaps the greatest challenge in breast oncology is the personalisation of therapy through identiﬁcation of predictive biomarkers of tumour sensitivity. In the neoadjuvant setting, dynamic changes in biomarkers can also be assessed either through serial tumour biopsy, blood draw for circulating tumour cells (CTCs) and other markers or molecular imaging to assess tumour metabolic pathways or drug distribution. All of these approaches are currently under investigation in neoadjuvant trials of HER2-targeted agents. Although it is beyond the scope of this paper to review all such data, some examples merit special mention. In the study of Holmes et al. all patients had core needle biopsies at baseline and 2 weeks into HER2-targeted therapy (Table 3).62 Results were analysed based on the subsequent achievement of pCR in the breast and demonstrated that resistant tumours were signiﬁcantly more likely to have intact PI3K, autophagy and stem cell proliferation pathways. Differences between treatment arms (trastuzumab vs. lapatinib vs. combination) were also detected although patient numbers were small and these results will require veriﬁcation in the translational studies of larger trials such as NeoALTTO,60 GeparQuinto61 and NeoSphere.64 Translational results from the GeparQuinto study have already been published for circulating biomarkers.83 In particular, a decrease in levels early after therapy initiation was predictive of response to lapatinib-based but not trastuzumab-based treatment. CTCs may also be useful biomarkers of prognosis and response to therapy, however they are only detectable in a minority of patients undergoing neoadjuvant therapy, limiting their clinical utility with current detection methods. Intriguingly, in the GeparQuattro neoadjuvant study, of the 22% (46/213) of patients with P1 CTC/ 7.5 mL sample, HER2-overexpressing CTCs were found in 8 patients with HER2-negative primary tumours.84 Similarly, CTCs scored HER2-negative or weakly HER2-positive before or after neoadjuvant therapy in 11 of 21 patients with HER2-positive primary tumours, potentially identifying a mechanism of trastuzumab resistance.84 There was no correlation between CTC levels and pCR in this or the NeoALTTO study, in which a similar low percentage of patients had detectable CTCs.85 The neoadjuvant setting provides an ideal testing ground for agents, where relatively small trials, with carefully conducted sequential biopsy and correlative biomarker studies, are taking us closer to the goal of personalised medicine. Perhaps the best example of this is the I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2; NCT01042379), which seeks to identify improved treatment regimens for subsets of patients on the basis of molecular characteristics (biomarker signatures) of their disease. The trial design is adaptive such that regimens that show a high Bayesian predictive probability of being more effective than standard therapy will graduate from the trial with their corresponding biomarker signature(s) and regimens will be dropped if they show a low probability of improved efﬁcacy. Imaging in the I-SPY 2 trial is with serial magnetic resonance imaging, which shows high sensitivity. There may be even greater utility in pursuing molecular imaging techniques such as positron emission tomography/computed tomography although preclinical data suggest that the more established radio-isotopes such as 18FDG may be suboptimal and clinical data are currently awaited.85,86 One ﬁnal consideration is the approach to the patient with residual cancer at surgery after ‘state of the art’ neoadjuvant therapy. Analysis of residual tumour for predictive biomarkers is a priority for future studies as these patients are known to have a poor prognosis, although a signiﬁcant proportion will not relapse despite the lack of pCR. Few data are available on the molecular 629 characteristics of residual disease so far although Mittendorf et al. examined 25 post-treatment tumours for HER2 expression by ﬂuorescence in situ hybridisation and found that 8 (32%) were HER2 negative, suggesting that alternate therapeutic strategies may be required in this subpopulation.87 The GeparQuinto study has explored this phenomenon pragmatically in women with triple-negative tumours without pCR randomising to weekly paclitaxel ± everolimus, patients without pCR to neoadjuvant chemotherapy were randomised to weekly paclitaxel ± everolimus.88 In a similar fashion, a randomised trial of T-DM1 versus continued post-operative trastuzumab is planned in women with HER2positive primary breast cancers and residual disease after neoadjuvant therapy. Conclusions Overall, the future is looking brighter for patients diagnosed with HER2-positive breast cancer with combinations of HER2-targeted agents showing great promise in improving outcomes. The neoadjuvant setting provides an ideal testing ground for novel agents, where relatively small trials, with carefully conducted sequential biopsy and correlative biomarker studies, are taking us closer to the goal of personalised medicine. Conﬂict of interest statement The authors take full responsibility for the content of this review article. Support for editorial assistance was provided by F. Hoffmann-La Roche, Ltd., Basel, Switzerland. The authors did not receive ﬁnancial compensation for this review article. Sacha Howell has received travel grants and honoraria for advisory boards from F. Hoffmann-La Roche Ltd. Arnd Honig has received travel grants and honoraria for advisory boards from, and acted as a consultant for, F. Hoffmann-La Roche Ltd. Susan Dent has received honoraria for speaking engagements and advisory boards from F. Hoffmann-La Roche Ltd. Max Mano has received honoraria for speaking engagements and travel grants from F. Hoffmann-La Roche Ltd. Basak Oyan has received travel grants from F. Hoffmann-La Roche Ltd. The authors have no other conﬂicts to declare. Author contributions Literature search: Sacha Howell and Basak Oyan Conception and design: All authors. Collection and assembly of data: All authors. Data analysis and interpretation: All authors. Manuscript writing: All authors. Final approval of manuscript: All authors. Acknowledgements We would like to acknowledge editorial assistance and literature searching provided by Gardiner-Caldwell Communications, support for which was provided by F. Hoffmann-La Roche Ltd., Basel, Switzerland. Appendix A. Supplementary data Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.ctrv.2013.01.002. 630 S. Dent et al. / Cancer Treatment Reviews 39 (2013) 622–631 References 1. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005;97:188–94. 2. van der Hage JH, van de Velde CJ, Mieog JS. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev 2007;2. http:// dx.doi.org/10.1002/1465185. CD005002. 3. Chevallier B, Roche H, Olivier JP, et al. Inﬂammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993;16:223–8. 4. Sinn HP, Schmid H, Junkermann H, et al. Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy. Geburtshilfe Frauenheilkd 1994;54:552–8. 5. Sataloff DM, Mason BA, Prestipino AJ, et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995;180:297–306. 6. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672–85. 7. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007;25:4414–22. 8. Penault-Llorca F, Abrial C, Raoelﬁls I, et al. Comparison of the prognostic signiﬁcance of Chevallier and Sataloff’s pathologic classiﬁcations after neoadjuvant chemotherapy of operable breast cancer. Hum Pathol 2008;39:1221–8. 9. Mukai H, Watanabe T, Ando M, et al. Assessment of different criteria for the pathological complete response (pCR) to primary chemotherapy in breast cancer: standardization is needed. Breast Cancer Res Treat 2009;113:123–8. 10. Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER2 therapy and personalized medicine. Oncologist 2009;14:320–68. 11. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2. N Engl J Med 2001;15:783–92. 12. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efﬁcacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as ﬁrst-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265–74. 13. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273–83. 14. Loibl S, von Minckwitz G, Blohmer JU, et al. pCR as a surrogate in HER2-positive patients treated with trastuzumab. Cancer Res 2011;71(S24):64s. Abstract S5– 4. 15. Burstein HJ, Harris LN, Gelman R, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003;21:46–53. 16. Jinno H, Sato T, Takahashi M, et al. A phase II neoadjuvant trial of concurrent trastuzumab and paclitaxel without anthracycline in women with HER2positive operable breast cancer. J Clin Oncol 2011;29(S15). Abstract e11070. 17. Coudert BP, Arnould L, Moreau L, et al. Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann Oncol 2006;17:409–14. 18. Paepke S, Kiechle M, Paepke D, et al. Interim analysis of the multicenter phase II HEDON trial evaluating pathological response to pre-operative docetaxel and docetaxel+trastuzumab (T) in locally advanced breast cancer (BR) stratiﬁed by HER2-status. J Clin Oncol 2009;27(S15). Abstract e11512. 19. Sawaki M, Iwata H, Sato Y, et al. Phase II study of preoperative systemic treatment with the combination of docetaxel and trastuzumab in patients with locally advanced HER-2-overexpressing breast cancer. Breast 2005;19:370–6. 20. Bines J, Murad A, Lago S, et al. Weekly docetaxel (TaxotereÒ) and trastuzumab (HerceptinÒ) as primary therapy in stage III, HER-2 overexpressing breast cancer: A Brazilian multicenter Study. Breast Cancer Res Treat 2003;82(S1):S56. Abstract 243. 21. Masuda N, Ando M, Aogi K, et al. Randomized phase II study of neoadjuvant chemotherapy and trastuzumab for operable breast cancer with overexpression of HER2. J Clin Oncol 2009;27(15S):S22. Abstract 565. 22. Chollet PJ, Dubray P, Durando X, et al. Pathologic complete response (pCR) in HER2 positive breast cancer to sequential FEC 100-docetaxel (D) plus trastuzumab (T) neoadjuvant chemotherapy (NCT). J Clin Oncol 2009;27(S15). Abstract e11560. 23. Saeki T, Aogi K, Nakamura S, et al. Multicenter phase II study of primary systemic therapy epirubicin/cyclophosphamide followed by docetaxel plus concurrent trastuzumab for HER2-positive advanced breast cancer. J Clin Oncol 2010;28(S15):S112. Abstract 681. 24. Untch M, Fasching PA, Konecny GE, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 2011;29:3351–7. 25. Blakely L, Somer B, Keaton M, et al. Neoadjuvant dose-dense sequential biweekly epirubicin and cyclophosphamide followed by docetaxel and trastuzumab for HER2+ operable breast cancer. J Clin Oncol 2009;27(S29). Abstract 595. 26. Robidoux A, Buzdar AU, Quinaux E, et al. A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-ﬂuorouracil/ epirubicin/cyclophosphamide in locally advanced breast cancer. Clin Breast Cancer 2010;10:81–6. 27. Hyams D, Leichman G, Klein P, et al. Phase II trial of neoadjuvant pegylated liposomal doxorubicin with paclitaxel and trastuzumab in patients with operable Her2-positive breast cancer. Cancer Res 2009;69(S3):24. Abstract 1098. 28. Antón A, Ruiz A, Plazaola A, et al. Phase II clinical trial of liposomalencapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003–03 study. Ann Oncol 2011;22:74–9. 29. Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010;28:2024–31. 30. Chia S, Bryce C, Pansegrau G, et al. Phase II trial of neoadjuvant sequential FEC100 followed by docetaxel, carboplatin and trastuzumab (TCH) for HER-2 over-expressing locally advanced breast cancer (LABC): A multi-centre study from British Columbia. Breast 2009;18(S1):S6. Abstract 0170. 31. Al-Tweigeri TA, Ajarim DS, Alsayed AA, et al. Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer. Med Oncol 2010;27:571–7. 32. Sánchez-Muñoz A, Dueñas-García R, Jaén-Morago A, et al. Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination?: results from a phase II trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast cancer patients. Am J Clin Oncol 2010;33:432–7. 33. Hurley J, Doliny P, Reis I, et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 2006;24:1831–8. 34. Coudert BP, Largillier R, Arnould L, et al. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. J Clin Oncol 2007;25:2678–84. 35. Dirix LY, Prove A, Sweldens C, et al. Phase II study of docetaxel, carboplatin and trastuzumab (THC) in patients with locally advanced breast cancer. J Clin Oncol 2007;25(S15):S18. Abstract 1062. 36. Bayraktar S, Bayraktar UD, Reis IM, et al. Neoadjuvant dose-dense docetaxel, carboplatinum, and trastuzumab (ddTCH) chemotherapy for HER2 overexpressing breast cancer. J Clin Oncol 2009;27(S). Abstract e11557. 37. Zeynalova KR, Vishnevskaya YV, Ganshina IP. High pathological complete response rate of neo-adjuvant combination of docetaxel, carboplatin and trastuzumab in patients with HER2-overexpressing breast cancer: preliminary results. Eur J Cancer 2008;8(S):93–4. 38. Sikov WM, Dizon DS, Strenger R, et al. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. J Clin Oncol 2009;27:4693–700. 39. Chen X, Chen C, Wu J, et al. Weekly paclitaxel plus carboplatin +/- trastuzumab in preoperative therapy of Her2-neu over-expressing breast cancer: a pilot phase II study. Breast 2009;18(S1):63–4. Abstract 0180. 40. Tripathy D, Moisa C, Gluck S. An open-label study of capecitabine (C) and docetaxel (D) as neoadjuvant treatment for patients with recently diagnosed HER2-neu negative (HER2-) breast cancer (BC) plus trastuzumab (T) for HER2neu positive (HER2+) BC. Eur J Cancer 2007;5(S):223. Abstract 2129. 41. Perez Manga G, Khosravi-Shahi P, Izarzugaza Peron Y, et al. Phase II study of neoadjuvant treatment with docetaxel, capecitabine, and trastuzumab in HER2-positive locally advanced or inﬂammatory breast cancer: TXH trial. J Clin Oncol 2009;27(S15). Abstract e11581. 42. Wildiers H, Neven P, Christiaens MR, et al. Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer. Ann Oncol 2011;22:588–94. 43. Limentani SA, Brufsky AM, Erban JK, et al. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. J Clin Oncol 2007;25:1232–8. 44. Im SA, Lee KS, Ro J, et al. Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07–01. Breast Cancer Res Treat 2012;132:589–600. 45. Harris LN, Eklund AC, Carter S, et al. HER2 tumors are heterogeneous, clinically, molecularly, and in response to preoperative trastuzumab: pathway analysis of gene expression proﬁles from three breast cancer datasets. Breast Cancer Res Treat 2007;106(S1):S87. Abstract 2009. 46. Torrisi R, Magni E, Dellapasqua S, et al. Trastuzumab and oral vinorelbine (+/endocrine therapy) as primary therapy in patients (pts) with HER-2/neu positive breast cancer. Breast Cancer Res Treat 2006;100(S1):148. Abstract 3071. 47. Torrisi R, Cardillo A, Cancello G, et al. Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-ﬂuorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inﬂammatory breast cancer. Clin Breast Cancer 2010;10:483–8. 48. Zubkus JD, Daniel DB, Eakle JF, et al. Neoadjuvant ixabepilone/carboplatin/ trastuzumab in HER2-positive locally advanced breast cancer: A Sarah Cannon S. Dent et al. / Cancer Treatment Reviews 39 (2013) 622–631 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. Research Institute phase II trial. J Clin Oncol 2011;29(S15 Pt 1):S75. Abstract 621. Smith JW, Buyse M, Rastogi P, et al. Epirubicin plus cyclophosphamide followed by docetaxel plus trastuzumab and bevacizumab as neoadjuvant therapy for HER2-positive locally advanced breast cancer (LABC) or as adjuvant therapy for HER2-positive pathologic stage III breast cancer (PS3BC): a phase II trial of the NSABP Foundation Research Group. J Clin Oncol 2009;27(S15 Pt 1):S26. Abstract 580. Viens P, Pierga J, Petit T, et al. Primary efﬁcacy analysis of a phase II study of neoadjuvant bevacizumab (BEV), chemotherapy (CT), and trastuzumab (H) in HER2-positive inﬂammatory breast cancer (IBC): BEVERLY2 study. J Clin Oncol 2011;29(S15 Pt 1):S52. Abstract 531. Yardley DA, Raefsky E, Castillo R, et al. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer. Clin Breast Cancer 2011;11:297–305. Chang JCN, Mayer IA, Forero-Torres A, et al. TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2overexpressing breast cancer. J Clin Oncol 2011;9(S15 Pt 1):S46. Abstract 505. Callahan RD, Patel R, Chan D, et al. Phase II trial of presurgical treatment with trastuzumab (H) or lapatinib (Ty) or the combination of trastuzumab and lapatinib (H+Ty), followed by six cycles of docetaxel (T) and carboplatin (C) with trastuzumab (TCH) or lapatinib (TCTy) or the combination of trastuzumab and lapatinib (TCHTy) in patients with HER2+ breast cancer. Cancer Res 2010;71(S):169S. Abstract P1-11-12. Kaklamani VG, Siziopikou K, Scholtens D, et al. Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib. Breast Cancer Res Treat 2012;132:833–42. Boussen H, Cristofanilli M, Zaks T, et al. Phase II study to evaluate the efﬁcacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inﬂammatory breast cancer. J Clin Oncol 2010;28(20):3248–55. Buzdar AU, Ibrahim NK, Francis D, et al. Signiﬁcantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676–85. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010;375:377–84. Pierga JY, Delaloge S, Espié M, et al. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res Treat 2010;122:429–37. Steger G, Greil R, Jakesz R, et al. Final results of ABCSG-24, a randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer and comparing ED/EDC plus trastuzumab (T) to ED/EDC as neoadjuvant treatment for early HER-2 positive breast cancer. Cancer Res 2009;69(S24):S64s. Abstract 1081. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012;379:633–40. Untch M, Loibl S, Bischoff J, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 2012;13:135–44. Holmes FA, Nagarwala YM, Espina VA, et al. Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy. J Clin Oncol 2011;29(S15):46s. Abstract 506. Guarneri V, Frassoldati A, Bottini A, et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol 2012;30:1989–95. Gianni L, Pienkowski T, Im YH, et al. Efﬁcacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inﬂammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:25–32. Dawood S, Gonzalez-Angulo AM, Peintinger F, et al. Efﬁcacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 631 retrospective review of the M.D. Anderson experience. Cancer 2007;110:1195–200. Bayraktar S, Gonzalez-Angulo AM, Lei X, et al. Efﬁcacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer 2012;118:2385–93. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Breast cancer screening and diagnosis, v.1.2010. <http:// demystifyingmedicine.od.nih.gov/DM10/0413-BreastCancer/NCCN%20breastscreening.pdf/>; 2012 [01.05.12]. Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;20:1319–29. Aebi S, Davidson T, Gruber G, et al. ESMO guidelines working group. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22(S6):vi12–24. Robidoux A, Tang G, Rastogi P, et al. Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41. J Clin Oncol 2012;30(Suppl.). Abstract LBA506. de Azambuja E, Bedard PL, Suter T, et al. Cardiac toxicity with anti-HER-2 therapies-what have we learned so far? Target Oncol 2009;4:77–88. Moy B, Goss P. Lapatinib-associated toxicity and practical management recommendations. Oncologist 2007;12:756–65. Schneeweiss A, Chia S, Hickish T, et al. Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline-free standard regimen: a randomized phase II study (TRYPHAENA). Cancer Res 2011;7(S):112s. Abstract S5–S6. Bozovic-Spasojevic I, Azim HT, Paesmans M, et al. Neoajduvant anthracycline and trastuzumab for breast cancer: is concurrent treatment safe? Lancet Oncol 2011;12(3):209–11. Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109–19. Bedard PL, de Azambuja E, Cardoso F. Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer. Curr Cancer Drug Targets 2009;9:148–62. Burstein HJ, Sun Y, Dirix LY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010;28:1301–7. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008;68:9280–90. Vogel CL, Burris HA, Limentani S, et al. A phase II study of trastuzumab-DM1 (TDM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+metastatic breast cancer (MBC): ﬁnal results. J Clin Oncol 2009;27(S15):S44. Abstract 1017. Herceptin. EMA/CHMP/897580/2011, European Medicines Agency, 2011. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809–20. Pivot X, Romieu G, Bonnefoi H, et al. PHARE Trial results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer. Ann Oncol 2012;23(Suppl. 9):ixe2. Abstract LBA5. Witzel I, Loibl S, von Minckwitz G, et al. Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial. Br J Cancer 2012;107:956–60. Riethdorf S, Müller V, Zhang L, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010;16:2634–45. Azim Jr HA, Rothe F, Aura CM, et al. Correlation between circulating tumor cells (CTCs), PET/CT response and pathological complete response (pCR) in primary Her2-positive breast cancer patients: a sub-study from the NeoALTTO trial. Ann Oncol 2012;23(Suppl. 9):ix98. Abstract 255PD. Shah C, Miller TW, Wyatt SK, et al. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clin Cancer Res 2009;15:4712–21. Mittendorf EA, Wu Y, Scaltriti M, et al. Loss of HER2 ampliﬁcation following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 2009;15:7381–8. von Minckwitz G, Eidtmann H, Loibl S, et al. Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol 2011;22:301–6.
© Copyright 2019